The nasal spray Neffy is the first non-injectable epinephrine to treat the life-threatening allergic response ARS Pharmaceuticals, Inc. The first-ever needle-free alternative to the EpiPen and similar ...
A committee of the Food and Drug Administration's outside advisers voted Thursday in favor of an epinephrine nasal spray product, clearing a key hurdle for what could soon be the first needle-free ...
The Food and Drug Administration approved the first needle-free alternative to the EpiPen on Friday, a single-use epinephrine nasal spray for the emergency treatment of allergic reactions, including ...
For patients in cardiac arrest, administering epinephrine helps to restart the heart but may increase the overall likelihood of death or debilitating brain damage, according to a study. The study ...
Please provide your email address to receive an email when new articles are posted on . Fear of needles leads to delayed deployment of autoinjector epinephrine, impacting outcomes. Dry powder ...
Vasopressin is an alternative to epinephrine for vasopressor therapy during cardiopulmonary resuscitation, but clinical experience with this treatment has been limited. We randomly assigned adults who ...
Anaphylaxis symptoms might subside after epinephrine treatment, but they could return, even hours later. Always go to the ER after an anaphylactic reaction in case you need follow-up care. There are ...
neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater. INDICATION AND IMPORTANT ...
The Food and Drug Administration, in a surprise move, has decided not to approve an epinephrine nasal spray that would have been the first needle-free alternative to epinephrine autoinjectors, ...
InvestorsHub on MSN
ARS Pharmaceuticals stock rises after Japan approves needle-free epinephrine spray
Shares of ARS Pharmaceuticals Inc. (NASDAQ:SPRY) climbed 7% on Friday following regulatory approval in Japan for the ...
Shares in ARS Pharmaceuticals were in freefall in pre-market trading this morning as it emerged that the FDA had declined to approve its application for its lead product, aiming to become the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback